NZ187908A - Pharmaceutical, veterinary, and dietary formulations containing (all-z)-5,8,11,14,17-eicosapentaenoic acid - Google Patents

Description

New Zealand Paient Spedficaiion for Paient Number 1 87908 NEW ZEALAND PATENTS ACT, 1953 No.: Date: COMPLETE SPECIFICATION "FATTY ACID AND DERIVATIVES THEREOF, AND FORMULATIONS CONTAINING THEM FOR USE IN TREATMENT OR PROPHYLLAXIS OF THROMBO-EMBOLIC CONDITIONS." jfc/We, THE WELLCOME FOUNDATION LIMITED of 183-193 EustOXl Road, London, N.W.I. 2BP a company incorporated in England. hereby declare the invention for which / we pray that a patent may be granted to /us, and the method by which it is to be performed, to be particularly described in and by the following statement:- 1 p. 7 3 0 8 X15Ir" The present invention relates to the treatment or prophylaxis of thrombo -embolic conditions..

Although it is known that many substances can affect platelet aggregation, it cannot be predicted, from a knowledge of the effect of a particular substance on aggregation of platelets, whether or not the substance will have an inhibitory or stimulatory (or neutral) effect on thrombus formation iri vivo. This is largely because it is not known what initiates formation of a thrombus or embolus in, for example, strokes or myocardial infarction. As an example of this unpredictability, aspirin is a good inhibitor of platelet aggregation in vitro and in vivo, but it is not an antithrombotic agent, in particular it cannot disperse a preformed thrombus.

M.J. Silver, J.B. Smith, et al., (Prostaglandins Dec. 1973, Vol. 4, No. 6, pages 863 to 875) i showed in vitro that many compounds can influence the platelet aggregating effects produced by the dietary component arachidonic acid (5,8,11,14-eicosatetraenoic acid, alternatively C20:4; n-6 acid i.e. a fatty acid containing 20 carbon atoms having 4 double bonds, the one at the highest numbered position being at a position 6 bonds from the end of the molecule remote from the carboxyl group, and n._ being the number of carbon atoms in the straight chain). These in vitro ] 3 7 9 0 8 . -39-5-5- tests in human citrated platelet rich plasma, cannot be unambiguously related to in vivo behaviour in a thrombus formation-prone mammal, including man. M.J. Silver et al. found in their tests that the platelet aggregation induced by arachidonic acid, as sodium arachidonate, can be inhibited by'many materials including adenosine; g-naphthol; nonsteroidal, anti-inflammatory agents, such as indomethacin, sodium salicylate and aspirin; unsaturated fatty acids, such as 11,14,17-eicosatrienoic acid; 8 ,11,14-eicosatrienoic acid (dihomo-^-linolenic acid, DHLA); 5,8,11,14,17-eicosapentaenoic acid; 5,8,11,14-eicosatetraynoic acid; and 4,7,10,13,16,19-docosahex3enoi'C v acid; and human albumin. They also found that the 4 platelet aggregation induced by collagen and a second wave of platelet aggregation induced by adenosine diphosphate (ADP) could be inhibited by g-naphthol, aspirin, 8,11,14-eicosatetraenoic acid, 5,8,11,14,17-eicosapentaenoic acid and human albumin. Silver £t al. further found that various fatty acids on their own did not induce platelet aggregation. The acids they mentioned were 8,11,14-eicosatrienoic acid; 11,14,17-eicosatrienoic acid; 5,8,11,14,17-eicosapentaenoic acid, 5,8,11,14-eicosatetraynoic acid; 4,7,10,13,16,19-docosahexaenoic acid; linolenic acidj linoleic acid; oleic acid; arachidic acid; stearic acid; and decanoic acid. 1 879 0 8 -X3r56- Silver et al_. appear to conclude that arachidonic acid has an' important place in hemostasis and thrombosis, and that its effects can be inhibited in vitro by various compounds, particularly albumin. They suggested that albumin may be an important controlling factor in hemostasis and that the ability of albumin to bind arachidonic acid in circulating blood might be the my it inhibits the effects of arachidonic acid. They further suggested this binding capacity may depend on, for example, the availability of binding sites and the competition between arachidonic acid and other fatty acids and other classes of substances. Presumably, therefore, the more competitive substances available, the more free arachidonic acid would be available and the more likely platelet aggregation would be and so, * if these phenomena were to be related, the more likely thrombus formation would be.

Various attempts have been made to investigate in man the effects of various fatty acids on diseases involving thrombus formation, but without any clear conclusions emerging.

For example, the Norwegian Vegetable Oil Experiment of 1965-66 was carried out before the work of Silver et a_l. and was reported by H. Natvig, Chr. F. Borchgrevink, et_ al in Scand. J. Clin. Lab. Invest; 22, Suppl. 105, 1-20, (1968). The study compared the effects on human mortality rates caused by various coronary heart diseases, including myocardial 18^9 08 infarction, of two diets, one containing sunflower seed oil (about 631 of linoleic acid) and the other containing linseed oil (about 55Bs of linolenic acid); 10 ml. of either oil be taken per day. The group taking the more highly unsaturated linolenic acid was found to be more at risk than the group taking the linoleic acid.

Linoleic acid, and, in rats, eicosapentaenoic and ? docosahexaenoic acids are known to decrease blood plasma cholesterol levels^ which are believed to be connected with atheroschlerosis. Atherosclerosis is often found in persons who have suffered from a myocardial infarct. However, there appears to be no causal relationship, because Robertson (Lancet, (1959), i, 44) found that in Jamaica, although extensive atherosclerosis is regularly found" in the native population at necropsy, it is very seldom associated with secondary thrombi or with myocardial infarction. Further, myocardial infarcts can occur in the absence of highly developed atherosclerosis.

Yet another possible dietary factor that has been suggested (P.B. Kernoff, A.L. Willis, K.J. Stone, J.A. Davis and G,P. McNicol, British Med. J., 1977, 2, 1441-1444) as helping to inhibit thrombosis is DHLA.

DHLA is a biosynethetic precursor of prostaglandin E^ (PGE^), which is a powerful inhibitor of platelet function, and is said to be attractive as an antithrombotic agent. It was found that there was, as hoped, a rise (mean 55?-) in production of the desirable .1 3 7 9 0 8 -XI55- PGE^, but in six men out of the eight tested there was also a rise (mean 33 S) in production of the undesirable prostaglandin E2 (PGE2). Furthermore, these results were not clearly dose related. There was also a lox^ering of heparin-neutralising activity of plasma and this activity has been found, to be high in thrombotic states. However, the authors did not know the extent to which lieparin-neutralising activity reflects basic pathological mechanisms, and so its relationship with thrombosis was unclear.

The authors of the paper speculated that "Perhaps small doses of DHLA may be equally if not more effective than major dietary manipulations in preventing and treating these conditions" i.e. atherosclerosis and coronary heart disease. However, the author of an editorial in the same edition of the Journal (pages 1437 and 1438) was more cautious and thought that "Trials of agents and regimens that modify the platelet prostaglandin mechanisms must be carried out before we can tell whether the results obtained by McNicol and his colleagues have any clinical application". The reasons for his caution lay in the ignorance that exists of the mechanisms involved in vivo in thrombotic situations, when investigative tests have only been carried out on shed blood, \ This at least partially attractive work with DHLA throws some doubt on the frequently quoted view 1 8 7 9 0 8. that highly unsaturated fatty acids in the diet are more beneficial than their more saturated analogues, especially as the even less saturated linoleic and linolenic acids can be metabolised to DHLA. This doubt is strengthened by the fact that arachidonic acid which is undesirable (see Silver et. al and Kernoff ert al above) is even more unsaturated (4 carbon-carbon double bonds) than DHLA (three carbon- carbon double bonds).

We have now surprisingly found that among the many fatty acids (all Z)-5,8,11,14,17-eicosapentaenoic acid or its salts, esters or amides can be used to treat effectively, or provide effective prophylaxis against, thrombo-embolic conditions, herein- Kr n after referred to simply as thrombosis. Examples of conditions Were our findings may be useful are in the treatment or prophylaxis of cardiovascular disease mediated by the formation of a thrombus or thrombi, for example, myocardial infarction, strokesj o;r deep vein thrombosis "during surgical operations.

We have found that (all Z)-5,8,11,14 ,17-eicosapentaenoic acid (hereinafter referred to simply as eicosapentaenoic acid) when injected intravenously into rabbits increases their bleeding time, thus demonstrating a decrease in the tendency of the blood to produce thrombi or adhere to damaged tissue. When infused into rabbit lung, eicosapentaenoic acid gives rise to a substance which has a powerful anti-aggregatory action action on blood platelets. Eicosapentaenoic acid also has the unusual and important ability to disperse already formed thrombi. 187908 IBrS5- For example, blood from an anaesthetised rabbit was allowed to drip over a continuously-weighed collagen strip taken from the Achilles tendon of another rabbit. As the blood flowed over the strip? platelets and other cells adhered to it to form a thrombus until there was no further gain in weight of the strip. The blood was returned to the. first rabbit under gravity. When eicosapentaenoic acid was infused into the blood passing over the loaded strip a decrease in weight was observed, showing that at least a part of the aggregated platelets and other cells had been disaggregated from the loaded strip.

This ability of eicosapentaenoic acid to bring about disaggregation of thrombus is important in the treatment of thrombosis, and also in its prophylaxis.

We have also found that human platelets> when pre-incubated with eicosapentaenoic acid and then incubated xirith arachidonic acid and stimulated with ADP, aggregate less readily than when the pre-incubation is carried out with arachidonic acid. This suggested to us that, if human platelets could be 'primed* with eicosapentaenoic acid, they would be less susceptible to ADP stimulation and so less liable to form thrombi.

The dose of eicosapentaenoic acid needed for therapeutic "or prophylactic effect will vary with the *3rreroute of administration and the nature of the condition being treated, but will generally be at least 1 gram (g), preferably from 1.5 to 3g. per day. This is the dose for an average 70kg. man and the dose for other men or animals will vary prorata according to their weight, ie. about 20 to 4Qng/kg, Eicosapentaenoic acid is known to be present cod liver oil and in othei* oils, e.g. menhaden oil, from which it may be extracted by methods known in the art or described in the literature. The eicosapentaenoic acid may also be synthesised by conventional methods of synthetic organic chemistry. The route chosen will depend on the availability of suitable starting materials. In practice the route used will >. depend on the relative costs of the various routes available to provide eicosapentaenoic acid of the right quality for human medical or veterinary use.

The amounts of eicosapentaenoic acid in naturally occurring or readily extractable materials such as cod liver oil or menhaden oil are such that it would not be possible to obtain the desired amount of eicosapentaenoic acid by administering them without also administering too many calories in the form of other fatty acids. Furthermore, as cod liver oil Tand other fish oils) is rich in vitamin A (at least 850 international- units (I.U.) per gram) and vitamin D Cat least 851.U. per gram) administering enough cod liver oil 1 879 to give the necessary amount of eicosapentaenoic acid would administer amounts of these vitamins greatly exceeding the recommended daily dose for humans and would lead to hyper-vitaminosis. The 5 recommended daily dose is 5000 I.U. for vitamin A and 400 I.U. for vitamin D in humans. In the U.S.A. the Food and Drugs Administration has laid down that the daily intake of vitamin A should not exceed 10,000 I.U. and of vitamin D should not 10 exceed 400 I.U. Amounts above this require a doctor's prescription.

Therefore to avoid complications, which may arise through the recipient receiving vitamin doses for other medicinal reasons, or at his or her own 15 instigation, a formulation is preferably provided which comprises eicosapentaenoic acid, or a pharma-ceutically acceptable salt, ester or amide thereof, and a pharmaceutically acceptable carrier, the formulation being substantially free of vitamins.

Because of the complex and to some extent uncertain effects of unsaturated acids other than eicosapentaenoic acid a formulation is preferably provided comprising eicosapentaenoic acid, or a pharmaceutically acceptable salt, ester, or amide 25 thereof, and a pharmaceutically acceptable carrier, the formulation being substantially free of other unsaturated acids, or their salts, esters or amides 1 879 0 -X1SS- The excessive calorie intake mentioned above, if, for example, cod liver oil or menhaden oil were used as the source of the eicosapentaenoic acid, may be largely overcome, although some 5 control of calorie intake in the remainder of the diet will still generally be necessary, by providing a formulation comprising eicosapentaenoic acid, or a pharmaceutically acceptable salt, ester or amide thereof, and a pharmaceutically acceptable carrier, 10 at least 50% by weight of the fatty acid content of the formulation being provided by eicosapentaenoic acid. However, if the eicosapentaenoic acid is to be administered without substantial modification of the recipient's diet, the acid should represent at 15 least 90%, preferably at least 95% or all, by weight of the fatty acid content of the administered material Arachidonic acid should preferably be absent or at most should be no more than 5% of the fatty acid content. For example a suitable quality of eicosa-20 pentaenoic acid comprises at least 90% of the acid, about 2% of each of arachidonic and dihomo-y-linolenic acids, the balance being palmitic and oleic acids, and other pharmaceutically acceptable materials. If vitamins are present, as they may be, they should 25 preferably not be present in amounts that would lead to their recommended daily intake being exceeded.

Formulations used according to the invention should also be free of saturated fatty acids and their salts, esters or amides. Preferably the formulations should be free of unsaponifiable materials. _ n _ 18 7 9 0 8 0£i5-5- By administering the eicosapentaenoic acid at at least 901 of the fatty acid content, it should be possible to avoid substantial alteration of the diet of the recipient, except perhaps to reduce 5 slightly the calorific content of the diet to allow for the extra calories from the eicosapentaenoic acid. However, if preferred, it may be possible to administer the eicosapentaenoic acid by replacing, say, butter and/or ordinary margarine by a special 10 margarine, e.g. of the emulsion type, formulated so that in normal usage the recipient would receive the required amount of the eicosapentaenoic acid. fCooking oils and fats may also be similarly formulated to contain the eicosapentaenoic acid.

The eicosapentaenoic acid need not be used as the acid itself but may be used as its pharmaceutically acceptable salts, esters or amides (which would be measured as their acid equivalents). Esters or amides which can be converted in. vivo to the acid and other 20 pharmaceutically acceptable products may be used, the preferred ester being the ethyl ester, but the methyl ester could perhaps also be used. The ester used is preferably not the cholesteryl ester as this would lead to some cholesterol being liberated, which may 25 lead to an increase in the serum cholesterol level.

The preferred salts are the sodium or potassium salts 18?908 -XiS-S" or any other pharmaceutically acceptable solid salt, as these are suitable for making into tablets. As eicosapentaenoic acid is highly unsaturated, it and its derivatives are readily oxidisable and formulations containing them should also contain anti-oxidants such as butylated hydroxy toluene, butylated hydroxy anisole, propyl gallate, a pharmaceutically acceptable quinone and a-tocopherol. Seme anti-oxidants may also contribute to the anti-thrombo-embolic effect.

Although it is preferred to administer the eicosapentaenoic acid (or its salts, esters or amides) (active compound) orally as this is a convenient route for routine administration, the active compound may ^administered by any route by which it may be successfully absorbed, e.g. parenterally (i.e. subcutaneously, intramuscularly or intravenously), rectally or, in the case of women, vaginally.

While it is possible for the active compound to be administered as such or as a simple mixture of components, it is preferable to present it as a pharmaceutical formulation. The formulations, both for veterinary and for human medical use, of the present invention comprise the active compound as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Formulations which contain 1879 0 8 eicosapentaenoic acid itself are preferably nonaqueous. Unit doses, e.g. tablets or capsules, of a formulation generally contain between 0.25 and 1.0 g, e.g. 0.5 g, of the active compound.

Generally three doses would be administered per day.

Formulations include those suitable for oral, rectal, vaginal, or parenteral (including subcu-taneous, intramuscular and intravenous) administration.

As eicosapentaenoic acid itself is a liquid 10 and tends to be unpalatable, it is preferably administered per orally in a capsule, for example one of soft gelatin, so that the eicosapentaenoic acid is not tasted. The capsule would generally be of a size to permit the required dose of eicosapenta-15 enoic acid to be administrable in one or two capsules at each dose taking and so a capsule would be generally about 0.5 ml in size. Another way of disguising the taste of the acid is to formulate it as an emulsion to be taken orally. The acid could also be formulated to 20 be spontaneously emulsifiable on being taken orally or being diluted before administration. An emulsion could also be of the multiple type e.g. the acid could be made into an oil-in-water emulsion with a pharmaceutically acceptable surface active agent and then this emulsion 25 could be emulsified in another oil, e.g. arachis oil. Alternatively, the acid could be similarly formulated ]87 9 0 8 Xl-5-5- into a water-in-oil emulsion and then this emulsion itself emulsified in water. The various types of emulsion could be presented as an oral gel or as a stiff emulsion, such as an emulsion margarine.

Other methods of disguising the taste are to absorb the acid onto a carrier or carriers such as kaolin, chalk, calcium phosphate, calcium sulphate, starch, a micro-crystalline celliilose or methyl or other modified cellulose. The resulting powder could be 10 sold as such or flavoured, and perhaps made into tablets or capsules, each tablet or capsule containing, for example, about 0.5 g of eicosapentaenoic acid as such or in the form of a solid derivative. Tablets ,\ could be film- or sugar-coated.

As for the salts, e.g. the sodium or potassium salts, these also tend to be unpalatable and tablets containing them, and representing for example 0.5 g of acid, should preferably be coated e.g. by film or sugar. Other methods of oral administration, e.g. 20 cachet or lozenge, may also be used in appropriate circumstances. The esters or amides may be formulated as for the acid or the salts, depending on whether they are liquid or solid, respectively.

If desired an oral formulation can be presented 25 as a sustained release formulation, for example as beads or micro-capsules in a capsule. 1 8 7908 A formulation for intramuscular administration could be in the form of an emulsion. A formulation for intravenous injection could be in the form of a mixture that would spontaneously emulsify upon 5 injection.

For rectal administration the acid or derivative could be formulated into a suppository in a trigly- } ceride base e.g. cocoa butter, a Witepsol or Suppocire or placed in a soft gelatin suppository capsule.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with the carrier which constitutes 15 one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into 20 the desired formulation. In the present specification and claims the term "carrier" includes one which is suitable for administration to a recipient and substantially encloses the active compound e.g. the body of a capsule or the coating on a coated tablet.

Accordingly, the present invention provides:-' 187908 (a) a pharmaceutical, veterinary or dietary anti-thrombotic formulation, adapted for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, comprising (all -Z)-5,8,11,14,17-eicosapentaenoic acid or a pharmaceutically acceptable salt, ester or amide thereof, and a pharmaceutically acceptable carrier, at least 50% of the fatty acid content of the formulation being provided by (all -Z)-5 ,8 ,11,14,17-eicosapentaenoic acid (i.e. as such or as a pharmaceutically acceptable salt, ester or amide thereof); (b) a pharmaceutical, veterinary or dietary anti-thrombotic formulation, adapted for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, comprising (all -Z)-5,8,11,14,17-eicosapentaenoic acid, or a pharmaceutically acceptable salt, ester or amide thereof, and a pharmaceuTr tically acceptable carrier, the formulation being substantially free of vitamins; (c) a pharmaceutical, veterinary or dietary anti-thrombotic formulation, adapted for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, comprising (all -Z)-5r8,11,14,17-eicosapentaenoic acid, or a pharmaceutically acceptable salt, ester or amide thereof, and a pharmaceutically acceptable carrier, the formulation being substantially free of other unsaturated acids (i.e. as such or as their derivatives); (d) an anti-thrombotic tablet formulation, for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, which comprises a solid derivative of (all -Z) - ,8,11,14,17-eicosapentaenoic acid; (e) a method of preparing a pharmaceutical formulation £ ^according to (a) , (b) , (c) or (d) ; gf / 187903 (f) an anti-thrombotic margarine, butter, cooking oil or fat formulation, for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, including (all -Z)-5,8,11,14,17-eicosapentaenoic acid or a salt, ester or amide thereof in an amount to provide at least 3% by weight of the eicosapentaenoic acid (i.e. as such or as a pharmaceutically acceptable salt, ester or amide thereof); (g) a method for the treatment or prophylaxis of a thromboembolic condition in a mammal, excluding man, which comprises administering a therapeutic or prophylactic anti-thrombo-embolic amount of (all -Z)-5,8,11,14,17-eicosapentaenoic acid or a pharmaceutically acceptable salt, ester or amide thereof; and (h) a method according to (g) using a formulation according to (a) , (b) , (c) or (d) .

We are aware of the Food and Drug Regulations 1973 and insofar as the invention relates to the sale in New Zealand of dietary formulations, we make no claim to use the invention in contravention of the law.

The present invention is illustrated by the following Examples. 1 -8 7 9 0 8 EXAMPLE 1 Blood from human volunteers that had not taken aspirin for the previous two weeks was collected from an ante-cubital vein in sodium citrate (0.11M), 1 part of citrate to 9 parts of blood. Plasma was separated from the blood by centrifugation at 160g (5 minutes) as a platelet rich plasma (PRP).

Studies on platelets were performed with arachidonic acid (AA) , eicosapentaenoic acid (ERA.) If prepared as potassium salts (see Schror, K., Moncada, S., Ubatuba, F.B., and Vane, J.R., Eur. J. Pharmac., 1978, 47^, 103) and with ADP or thrombin in a coagulation apparatus e.g. 'Fibromate' (Bie & Bernsted, Copenhagen, Denmark).

Aggregation was recorded both turbidimetrically and nephelometrically in a cylindrical cuvette, containing 300yl of PRP at 37°C and stirred magnetically at 800 rpm; alternatively a Payton dual channel aggregometer was used with 500yl PRP.

In contrast to AA, EPA did not induce aggregation in human PRP at concentrations of EPA (1.33, 2.66 and 5.3 mM) about 4 or more times greater than AA (0.33, 0.66 and 1.3 mM) . At lower concentrations in the range of from 0,01 to 0.5 mM EPA somewhat inhibited platelet aggregation induced by ADP (2;iM) in the human PRP. - 19 *"*"8 79 0 8 The anti-aggregating effect of EPA (0.065 mM) , however, was not due to its conversion by platelet cyclo-oxygenase because the anti-aggregating effect was present with aspirin-treated platelets which did not respond to AA (0.065 mM) but were aggregated by thrombin (0.04-0.4 U/ml), and the anti-aggregating effect was also present in first phase aggregation induced by ADP (2 to 5yM) in aspirin-treated platelet^.

EXAMPLE 2 Vascular tissue (thoracic and abdominal aorta) was obtained from freshly killed Tats. Approximately 100 mg of tissue was chopped and washed once in ice cold Tris buffer (0.05 M, pH 7.5). After* testing its ability to inhibit thrombin-induced platelet aggregation when added to the platelet cuvette, the tissue was washed several times in 10 ml of ice cold Tris buffer to remove blood and adhering platelets. The tissue was then quickly frozen to -60°C, crushed to a coarse powder and resuspended in five volumes of Tris buffer. This suspension of vascular tissue was kept on ice during the experiments and used for incubation studies.

Blood was obtained from the ante-cubital vein of human volunteers that had taken aspirin (1.5g per day) for the 3 days before blood sampling, Washed »W87908 human platelets were obtained from this blood as described by Vargaftig, B.B., Tranier, Y, and Chignard, M, (Prostaglandins, 1974 , 8^, 133). Aggregation tests were carried out as in Example 1.

To see if the suspension of vascular tissue could synthesise any material having an antiaggregatory effect on human platelets, platelets were obtained as described above from volunteers who had taken aspirin, sc^ that their platelets could not produce prostaglandin endoperoxides that could be utilized by the vascular tissue to make anti-aggregatory material. Moreover, washed platelets were used to avoid any possibility of the vascular tissue utilizing any AA in the plasma. Under these conditions anti-aggregating activity could be formed by the vascular tissue only from endogenous or exogenously added precursors.

The initial suspension of vascular tissue (10 to 50yl) described above inhibited aggregation induced by thrombin (0.04 to 0.4 U/ml). This inhibitory activity was abolished by repeated washing (5 to 20 times) of the tissue by centrifuging (30 seconds in an Eppendorff centrifuge), pouring off the supernatant and resuspending in fresh buffer CO.5 ml). The general of inhibitory activity against primary phase aggregation induced by ADP (2 to 5yM) or aggregation induced by thrombin CO.04 to 0,4 U/ml) could be restored by adding washed vascular tissue ^879 0 8 and EPA to the washed platelets from aspirin-treated volunteers. The generation of anti-aggregating activity was prevented by the pretreatment of the washed vasculaT tissue with indomethacin (5 to lOyg/ml). Thus, the vessel wall cyclo-oxygenase could utilise EPA to form anti-aggregating activity.

The anti-aggregating activity formed might have been due to displacement of endogenous AA by EPA and not to direct utilization of EPA. However, / * the same concentrations of DHLA incubated with washed vascular tissue did not lead to the formation of anti-aggregating material. - 22. - a 8790-8 EXAMPLE 3 The Effect of Eicosapentaenoic Acid on Bleeding Time In the Rabbit Four male New Zealand white rabbits (Ranch) weighing 2.0 to 2.5 kg were anaesthetized with sodium pentobarbitone (40 mg/kg). The marginal ear vein was cannulated for infusions (0.1 ml/min) of eicosapentaenoic acid. The potassium salt of eicosapentaenoic acid (95/6 pure and containing about 2% AA and 2% DHLA, balance C-l8 fatty acids) was dissolved in 50 mM Tris-HC1 buffer pH 8.0 kept on ice and shielded from light. Infusions of either the Tris vehicle or eicosapentaenoic acid were made 5 minutes before and continuously during the measurement of bleeding time.

The internal surface of the ear without the cannular was carefully shaved. The ear was transilluminated so that blood vessels were clearly visible. Cuts, approximately O.k cm long and deep enough to cause an upwelling of blood within 15 seconds, were made with a new scalpel blade in an area free of visible blood vessels and in a direction parallel to the nearest blood vessel. The cut was gently blotted every 15 seconds with filter paper (Whatman No.l).

Bleeding time was measured to the nearest 15 seconds from the time of incision until dots of blood were no longer visible on the filter paper. If there was a plasma exudate from the cut, the end point was »«■ ">7908 considered as the time when the exudate no longer had a reddish tinge. When bleeding time was longer than 10 minutes, the cut was then blotted every 30 seconds. The bleeding time at each dose was a mean of 3 estimations.

Two rabbits were pretreated with aspirin 100 mg/kg i«v. injection 4 hours before the experiment. Two rabbits were given 0.5 ml Tris pH 7*5 in k ml saline in the same way to act as controls. The results obtained are set out in Tables 1 and 2.

TABLE 1 Controls i.e. no aspirin EPA Dose jig/kg/min Bleeding Time* minutes Rabbit 1 Rabbit 2 0 3.5 3.0 50 16.0 100 19-8 16.5 200 **23-0 879 08 TABLE 2 Pretreated with aspirin 100 mg/kg i.v. injection k hours before test begun.

EPA Dose jig/kg/min Bleeding Time* minutes Rabbit 3 Rabbit k 0 -3 *t.7 100 7.3 f 6.3 200 ^•5 * *7«5 * Mean of 3 estimations ** Rate of infusion 0.2 ml/min.

Accordingly when treated with aspirin, the rabbits showed little or no increase in bleeding time.

A rabbit treated with 75% pure EPA gave similar results, after allowing for the lower purity of the acid.

EXAMPLE 4 atsBneaasamaammmm Conversion of Eicosapentaenoic Acid in the Circulation of the Dog Intravenous infusion of eicosapentaenoic acid -"1 — 1 (0.2 to 2 mg kg min ) caused systemic and pulmonary hypotension in chloralose anaesthetized dogs. Blood-bathed isolated strips of bovine coronary artery and rabbit coeliac artery are relaxed by the powerfully antiaggregatory material PGI^ (5 "to 10 ixg/ml). When treated with antagonists of catecholamines and angiotensin II, these bioassay tissues, bathed in arterial blood, - ^ 8 79 0 8 relaxed during infusion of eicosapentaenoic acid (0.6 — 1 —1 to 2 mg kg min , 2 dogs), equivalent to about 10 to ng/ml at the highest rates. In one of these dogs after administration of indomethacin (5 mg/kg), subsequent infusion of eicosapentaenoic acid (2 mg kg * — 1 min for 10 min) still caused hypotension but did not release any detectable activity in the bioassay tissues.

EXAMPLE 5 Disaggregating effect of Eicosapentaenoic Acid in the Rabbit Rabbits (2-3 kg) were anaesthetized with pentobarbitone sodium 30 mg/kg and heparinized (2000 U/kg). A carotid artery was dissected and blood was exteriorized and delivered with a roller pump to superfuse a strip of collagen from the Achilles tendon of a different rabbit. As the blood flowed over the tendon strip, the strip increased in weight over a period of 35 min, up to a maximum of from 180 to 200 mg. Thereafter any decrease in weight was due to platelet disaggregation.

Eicosapentaenoic acid infused intravenously (50-500 jug/kg/min) in five rabbits induced small disaggregating effects (approximately 20 mg). This effect of eicosapentaenoic acid could be inhibited by pre-treating the rabbits with aspirin (150 mg/kg). x5^5- 1 879 0 8 EXAMPLE 6 A soft gelatin capsule to contain about 0.5 ml was sterilised and then filled with a composition containing more than 90% - of EPA, .about 2% AA, about 2% DHLA with the. balance being palmitic and oleic acids. The capsule was then sealed.

The capsule used may be transparent or coloured, and may also be of the hard gelatin type or made of polymethyl methacrylate for'example.

EXAMPLE 7 A tablet formulation comprised:- Sodium eicosapentaenoate 281 mg Starch 62 mg Lactose 250 mg Polyvinyl pyrrolidone 3.5 mg Magnesium Stearate 3*5 mg Butylated hydroxy toluene 2 ppm TOTAL 600 mg The tablet was coated with sugar, although other coating agents could be used.

EXAMPLE 8 The formulation described in Example 7 in untabletted powder form may be used to fill hard gelatin capsules with 600 mg of the formulation. 2-7 - ***1 879 0 8 EXAMPLE 9 About 250 g of a conventional soft margarine formulation was thoroughly mixed with 8 g of eicosapentaenoic acid until a smooth consistency was reached.

EXAMPLE 10 Male New Zealand rabbits (2-2.5 kg) were given aspirin (10 or 100 mg/kg 'i.v.). A control group received only the. liquid vehicle used for dissolving the aspirin. Two to four hours later the animals 10 were anaesthetised with pentobarbitone and cutaneous bleeding time was measured as described in Example 3, -before and during the infusion of EPA (potassium salt-, 95% pure as used in Example 3) at different rates (1,50,200 or 400 yg/kg/min). Duplicate or triplicate 15 measurements were done for each condition. The results obtained are set out in Table 3 below. Aspirin (10 mg/kg) produced a small but significant (p <0.0001) increase in bleeding time, the average of triplicate determination in five rabbits was 489 ± 27 s (mean ± s.e.m.) compared 20 to the controls 278 ± 48 s. The value of 288 ± 11 s in the animals treated with a large dose (100 mg/kg) of aspirin was not significantly higher than the control.

In the group receiving no aspirin, EPA (1 yg/kg/ min) prolonged bleeding time by more than 100% 25 (p <0.00001). A further increase in bleeding time is observed at higher rates of infusion and a plateau 1 87908 ^revalue of about 1000 sec is attained at the rate of 50 ng/kg/min.

In the animals treated with aspirin (10 or 100 mg/kg) EPA failed to produce a significant 5 modification in the bleeding time.

TABLE 3 j- Pretreatment EPA jig/kg/min 0 1 50 200 400 None 278 ± 48 642 ± 69 861 ± 69 961 ± 87 1020 ± 89 - n = 8 n = 5 n = 5 n = 4 n = 4 ASA 10 mg/kg 489 ± 27 607 ± 97 678 ± 115 839 ± 160 693 ± 114 n = 5 n = 5 n = 5 n = 5 n = 4 ASA 100 mg/kg 288 ± 11 309 ±13 327 ± 82 428 ± 86 364 ± 26 n = 5 n = 3 n = 3 *3- ii n = 3 Mean bleeding time in seconds ± s.e.m. ASA = Aspirin 107908

Claims (33)

WHAT WE CLAIM IS:

1. A pharmaceutical, veterinary or dietary anti-thrombotic formulation, adapted for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, comprising (all -Z)-5,8,11,14,17-eicosapentaenoic acid, or a pharmaceutically acceptable salt, ester or amide thereof, and a pharmaceutically acceptable carrier, at least 50% by weight of the fatty acid content of the formulation being provided by (all -Z)-5,8,11,-14,17-eicosapentaenoic acid or a pharmaceutically acceptable salt, ester or amide thereof.

2. A formulation according to claim 1 in which at least 90% by weight of the fatty acid content of the formulation is provided by (all -Z)-5,8,11,14,17-eicosapentaenoic acid or a pharmaceutically acceptable salt, ester or amide thereof.

3. A formulation according to claim 2 in which at least 95% by weight of the fatty acid content of the formulation is provided by (all -Z)-5,8,11,14,17-eicosapentaenoic acid or a pharmaceutically acceptable salt, ester or amide thereof.

4. A formulation according to claim 1 in which the fatty acid content is all or substantially all (all -Z)-5,8,11,14,17-eicosapentaenoic acid or a pharmaceutically acceptable salt, ester or amide thereof.

5. A formulation according to any one of claims 1 to 3 which includes in its fatty acid content about 2% by weight 187908 of arachidonic acid, about 2% by weight of dihomo-y—linolenic acid, with the balance being palmitic and oleic acids, and other pharmaceutically acceptable fatty acids, or salts, esters or amides thereof.

6. A pharmaceutical, veterinary or dietary anti-thrombotic formulation, adapted for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, comprising (all -Z)-5,8,11,14,17-eicosapentaenoic acid, or a pharmaceutically acceptable salt, ester or amide thereof, and a pharmaceutically acceptable carrier, the formulation being substantially free of other unsaturated acids or derivatives thereof.

7. A formulation according to any one of claims 1 to 3 substantially free of other unsaturated acids or derivatives thereof.

8. A pharmaceutical, veterinary or dietary anti-thrombotic formulation, adapted for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, comprising (all -Z)-5,8,11,14,17-eicosapentaenoic acid, or a pharmaceutically acceptable salt, ester or amide thereof, and a pharmaceutically acceptable carrier, the formulation being substantially free of vitamins.

9. A formulation according to any one of claims 1 to 7 substantially free of vitamins.

10. A formulation according to any one of the preceding claims in which the eicosapentaenoic acid is present in the form of its sodium or potassium salt. 31 18 79 0 8

11. A formulation according to any one of claims 1 to 9 in which the eicosapentaenoic acid is present as its ethyl ester.

12. A formulation according to any one of claims 1 5 to 9 in which eicosapentaenoic acid itself is used.

13. A formulation according to any one of the preceding claims including an antioxidant.

14. A formulation according to any one of the preceding claims including a flavouring agent.

I® 15. a formulation according to any one of the t preceding claims in which the carrier is a solid.

16. A formulation according to claim 15 in which the carrier is or includes a capsule enclosing the remainder of the formulation. 15

17. A formulation according to any one of claims 1 to 14 in which the carrier is a liquid.

18. A formulation according to claim 17 in which the eicosapentaenoic acid, salt, ester or amide forms a disperse phase in the carrier liquid. 1-87908

19. A formulation according to claim 17 or 18 in a capsule.

20. A formulation according to any one of claims 1 to 15 in tablet form.

21. A formulation according to any one of the preceding claims in a form suitable for oral, parenteral, rectal, vaginal or intrapulmonary administration.

22. A formulation according to any one of the preceding claims in unit dosage form.

23. A formulation according to claim 22 containing 0.2 5 to l.G-g of (all -Z)-5,8,11,14,17-eicosapentaenoic acid.

24^ An anti-thrombotic tablet formulation, for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, which comprises a solid derivative of (all -Z)--5,8,11,14,17-eicosapentaenoic acid.

25. A method of preparing a formulation according to any one of the preceding claims comprising bringing the components into operative association with one another.

26. An anti-thrombotic margarine, butter, cooking oil or fat formulation, for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, including (all -Z) -5,8,11,14,17-eicosapentaenoic acid or a salt, ester or ^amide thereof in an amount to provide at least 3% by weight [Lof the eicosapentaenoic acid, in the form of the acid itself or a pharmaceutically acceptable salt, ester or amide thereof. - 33 - 1 879

27 . A margarine formulation according to claim 2 6 in the form of an emulsion margarine.

28. A formulation according to any one of the preceding claims substantially free of saturated fatty acids or their salts, esters or amides. 1879C8 uT?C8

29. An anti-thrombotic capsule formulation, for use in the treatment or prophylaxis of a thrombo-embolic condition in a mammal, containing (all -Z)-5,8,11,14,17-eicosapentaenoic acid or a pharmaceutically acceptable salt, ester or amide thereof substantially as hereinbefore described either in Example 6 or in Example 8.

30. A margarine formulation according to claim 2 6 substantially as hereinbefore described in Example 9.

31. A method for the treatment or prophylaxis of a thrcaribo-embolic condition in a maimial, excluding man, which comprises administering a therapeutic or prophylactic anti-thrombo-embolic amount of (all -Z)-5,8,11,14,17-eicosapentaenoic acid or a pharmaceutically acceptable salt, ester or amide thereof.

32. A method according to claim 31 in which from 1.5 to 3 grams per day are administered of (all -Z)-5,8,11,14,17-eicosapentaenoic acid, as such or as a salt, ester or amide thereof.

33. A method according to claim 31 or 32 in which a formulation according to any one of claims 1 to 24, 26 and 29 is used. - 35 - DATED THIS DAY OFB=-19 A. J. PARK & SON PER ji s. C-<=A AGENTS FOR THE APPLICANTS